Absci (ABSI) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Absci Revenue Highlights


Latest Revenue (Y)

$5.72M

Latest Revenue (Q)

$898.00K

Absci Revenue by Period


Absci Revenue by Year

DateRevenueChange
2023-12-31$5.72M-0.50%
2022-12-31$5.75M20.18%
2021-12-31$4.78M0.04%
2020-12-31$4.78M132.04%
2019-12-31$2.06M-

Absci generated $5.72M in revenue during NA 2023, up -0.50% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Absci Revenue by Quarter

DateRevenueChange
2024-03-31$898.00K165.68%
2023-12-31$338.00K-54.57%
2023-09-30$744.00K-77.90%
2023-06-30$3.37M165.33%
2023-03-31$1.27M-18.50%
2022-12-31$1.56M-34.28%
2022-09-30$2.37M136.43%
2022-06-30$1.00M22.34%
2022-03-31$819.00K-43.60%
2021-12-31$1.45M-5.65%
2021-09-30$1.54M111.40%
2021-06-30$728.00K-31.51%
2021-03-31$1.06M-61.03%
2020-12-31$2.73M197.82%
2020-09-30$916.00K62.41%
2020-06-30$564.00K-1.40%
2020-03-31$572.00K-

Absci generated $898.00K in revenue during Q1 2024, up 165.68% compared to the previous quarter, and up 57.68% compared to the same period a year ago.

Absci Revenue Breakdown


Absci Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceJun 21
Collaborative Revenue$136.00K
Technology Development Revenue$592.00K

Absci's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Technology Development Revenue (81.32%), and Collaborative Revenue (18.68%).

Absci Revenue Breakdown by Country

Quarterly Revenue by Country

CountryJun 21
Collaborative Revenue$136.00K
Technology Development Revenue$592.00K

Absci's latest quarterly revenue breakdown by geography, as of Jun 21: Technology Development Revenue (81.32%), and Collaborative Revenue (18.68%).

Absci Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
DTILPrecision BioSciences$48.73M$49.90M
RXRXRecursion Pharmaceuticals$44.58M$13.79M
CRBUCaribou Biosciences$34.48M$3.46M
VECTVectivBio$27.34M$676.00K
RLAYRelay Therapeutics$25.55M-
EXAIExscientia$24.96M$5.29M
AFMDAffimed$8.28M$155.00K
ABSIAbsci$5.72M$898.00K
XFORX4 Pharmaceuticals-$563.00K
AVROAVROBIO--
DAWNDay One Biopharmaceuticals-$20.07M
ZURAZura Bio--
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
GRPHLENZ Therapeutics--
ELEVElevation Oncology--
CFRXContraFect--
SANASana Bio--
HEPAHepion Pharmaceuticals--

ABSI Revenue FAQ


Absci's yearly revenue for 2023 was $5.72M, representing a decrease of -0.50% compared to 2022. The company's yearly revenue for 2022 was $5.75M, representing an increase of 20.18% compared to 2021. ABSI's yearly revenue for 2021 was $4.78M, representing an increase of 0.04% compared to 2020.

Absci's quarterly revenue for Q1 2024 was $898K, a 165.68% increase from the previous quarter (Q4 2023), and a -29.24% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $338K, a -54.57% decrease from the previous quarter (Q3 2023), and a -78.29% decrease year-over-year (Q4 2022). ABSI's quarterly revenue for Q3 2023 was $744K, a -77.90% decrease from the previous quarter (Q2 2023), and a -68.59% decrease year-over-year (Q3 2022).

Absci's revenue growth rate for the last 3 years (2021-2023) was 19.57%, and for the last 5 years (2019-2023) was 177.57%.